Literature DB >> 9093048

Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

M Biffi1, G Boriani, P Sabbatani, G Bronzetti, L Frabetti, R Zannoli, A Branzi, B Magnani.   

Abstract

OBJECTIVE: To evaluate the efficacy of head up tilt guided treatment with metoprolol and clonidine in preventing the recurrence of syncope in patients with malignant vasovagal syncope. PATIENTS: 20 patients (9 men and 11 women, mean age 33 (SD 17), range 14 to 62 years) with severe symptoms.
DESIGN: Randomised double blind crossover trial; efficacy was assessed by head up tilt testing.
RESULTS: Metoprolol was more effective than clonidine in abolishing syncope (19/20 v 1/20, P < 0.001) but clonidine showed some beneficial effects on time to syncope and severity of hypotension in 12 patients. During an average follow up of 15 (3) months there was a significant reduction in the recurrence of symptoms compared with the previous year in patients who had tilt up guided treatment (18 metoprolol, 1 clonidine).
CONCLUSIONS: Treatment guided by head up tilting is a reliable method of treating patients with malignant vasovagal syndrome. Metoprolol was an effective long term treatment for preventing syncope. High doses were more effective and a careful dose titration period helped to minimise withdrawal symptoms and side effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093048      PMCID: PMC484696          DOI: 10.1136/hrt.77.3.268

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  22 in total

1.  Reproducibility of head upright tilt table test results in patients with syncope.

Authors:  B P Grubb; D Wolfe; P Temesy-Armos; H Hahn; L Elliott
Journal:  Pacing Clin Electrophysiol       Date:  1992-10       Impact factor: 1.976

2.  Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope.

Authors:  J S Sra; V S Murthy; M R Jazayeri; Y H Shen; P J Troup; B Avitall; M Akhtar
Journal:  J Am Coll Cardiol       Date:  1992-02       Impact factor: 24.094

3.  Reproducibility of isoproterenol tilt-table tests in patients with syncope.

Authors:  R Sheldon; J Splawinski; S Killam
Journal:  Am J Cardiol       Date:  1992-05-15       Impact factor: 2.778

4.  Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome.

Authors:  B P Grubb; P Temesy-Armos; J Moore; D Wolfe; H Hahn; L Elliot
Journal:  Am J Cardiol       Date:  1992-04-01       Impact factor: 2.778

5.  Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease.

Authors:  X C Chen; M Y Chen; S Remole; Y Kobayashi; A Dunnigan; S Milstein; D G Benditt
Journal:  Am J Cardiol       Date:  1992-03-15       Impact factor: 2.778

6.  Differentiation of convulsive syncope and epilepsy with head-up tilt testing.

Authors:  B P Grubb; G Gerard; K Roush; P Temesy-Armos; L Elliott; H Hahn; C Spann
Journal:  Ann Intern Med       Date:  1991-12-01       Impact factor: 25.391

7.  In vivo microdialysis evidence for central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol.

Authors:  S Hjorth; T Sharp
Journal:  J Pharmacol Exp Ther       Date:  1993-05       Impact factor: 4.030

8.  Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole.

Authors:  J S Sra; M R Jazayeri; B Avitall; A Dhala; S Deshpande; Z Blanck; M Akhtar
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

9.  (-)-Penbutolol as a blocker of central 5-HT1A receptor-mediated responses.

Authors:  S Hjorth
Journal:  Eur J Pharmacol       Date:  1992-11-03       Impact factor: 4.432

10.  Permanent pacing for cardioinhibitory malignant vasovagal syndrome.

Authors:  M E Petersen; R Chamberlain-Webber; A P Fitzpatrick; A Ingram; T Williams; R Sutton
Journal:  Br Heart J       Date:  1994-03
View more
  8 in total

1.  [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004].

Authors:  K Seidl; A Schuchert; J Tebbenjohanns; W Hartung
Journal:  Z Kardiol       Date:  2005-09

2.  Twenty-four-hour urine NE level as a predictor of the therapeutic response to metoprolol in children with recurrent vasovagal syncope.

Authors:  Qingyu Kong; Xiaofei Yang; Zhifeng Cai; Yanyan Pan; Minmin Wang; Mengmeng Liu; Cuifen Zhao
Journal:  Ir J Med Sci       Date:  2019-02-13       Impact factor: 1.568

Review 3.  Neurocardiogenic syncope: aetiology and management.

Authors:  K A Gatzoulis; P K Toutouzas
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Strategy for the management of vasovagal syncope.

Authors:  Daniel M Bloomfield
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Current Management of Syncope: Treatment Alternatives.

Authors:  Carlos A. Morillo; Adrián Baranchuk
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-10

Review 6.  New approaches to the treatment and prevention of neurally mediated reflex (neurocardiogenic) syncope.

Authors:  Daniel P Melby; Joseph A Cytron; David G Benditt
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

7.  Clinical efficacy of beta1 selective adrenergic blockers in the treatment of neurocardiogenic syncope - a meta-analysis.

Authors:  Srikanth Vallurupalli; Smita Das
Journal:  Clin Pharmacol       Date:  2010-09-15

8.  Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: A case report.

Authors:  Jae Young Lee; Ho Seok Lee; Si-Bog Park; Kyu Hoon Lee
Journal:  World J Clin Cases       Date:  2022-09-06       Impact factor: 1.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.